Tumor Biol. DOI 10.1007/s13277-014-2964-z
RESEARCH ARTICLE
The tumor suppressor role of PAQR3 in osteosarcoma Zhiqiang Ma & Yanlong Wang & Taikui Piao & Zhaopeng Li & Hongyu Zhang & Zhixin Liu & Jianyu Liu
Received: 14 September 2014 / Accepted: 8 December 2014 # International Society of Oncology and BioMarkers (ISOBM) 2014
Abstract Osteosarcoma is the most common primary bone malignancy; however, the molecular mechanisms of development are not well understood. Progestin and AdipoQ receptors (PAQR3), a protein specifically localized in the Golgi apparatus, was recently characterized as a new tumor suppressor. Little is known about the expression and function of PAQR3 in osteosarcoma. Here, we showed that PAQR3 was downregulated in osteosarcoma tissues compared with the adjacent normal regions in 80 paired samples. Moreover, lower levels of PAQR3 were associated with metastasis in clinical osteosarcoma patients. In addition, overexpression of PAQR3 in the osteosarcoma cell line MG-63 inhibited cell proliferation, migration, and invasion by promoting ERK phosphorylation. Taken together, our results indicated that PAQR3 might act as a tumor suppressor in osteosarcoma, providing a novel diagnostic and therapeutic option for human osteosarcoma in the future.
Keywords Osteosarcoma . Tumor suppressor . PAQR3 . ERK1/2
Electronic supplementary material The online version of this article (doi:10.1007/s13277-014-2964-z) contains supplementary material, which is available to authorized users. Z. Ma : Y. Wang : Z. Li : H. Zhang : Z. Liu : J. Liu (*) Department of Orthopedic Surgery, The Second Hospital of Harbin Medical University, Harbin, Heilongjiang Province 150086, People’s Republic of China e-mail: [email protected] T. Piao Children’s Hospital of Harbin, Harbin, Heilongjiang Province 150010, People’s Republic of China
Introduction Osteosarcoma is the most common type of human primary malignant bone tumor, accounting for 60 % of all malignant childhood bone tumors [1–3]. Osteosarcoma usually occurs in the long bones, such as the femur, the tibia, or the humerus [4–6]. Approximately 50 % of these cases are localized near the knee region [7–9]. By combining surgery with other treatment (neoadjuvant chemotherapy and adjuvant chemotherapy), the 5-year survival of patients with no metastatic disease at diagnosis is about 60–70 % [10, 11]. Unfortunately, for patients who present with metastasis, the outcome is far worse at
RESEARCH ARTICLE
The tumor suppressor role of PAQR3 in osteosarcoma Zhiqiang Ma & Yanlong Wang & Taikui Piao & Zhaopeng Li & Hongyu Zhang & Zhixin Liu & Jianyu Liu
Received: 14 September 2014 / Accepted: 8 December 2014 # International Society of Oncology and BioMarkers (ISOBM) 2014
Abstract Osteosarcoma is the most common primary bone malignancy; however, the molecular mechanisms of development are not well understood. Progestin and AdipoQ receptors (PAQR3), a protein specifically localized in the Golgi apparatus, was recently characterized as a new tumor suppressor. Little is known about the expression and function of PAQR3 in osteosarcoma. Here, we showed that PAQR3 was downregulated in osteosarcoma tissues compared with the adjacent normal regions in 80 paired samples. Moreover, lower levels of PAQR3 were associated with metastasis in clinical osteosarcoma patients. In addition, overexpression of PAQR3 in the osteosarcoma cell line MG-63 inhibited cell proliferation, migration, and invasion by promoting ERK phosphorylation. Taken together, our results indicated that PAQR3 might act as a tumor suppressor in osteosarcoma, providing a novel diagnostic and therapeutic option for human osteosarcoma in the future.
Keywords Osteosarcoma . Tumor suppressor . PAQR3 . ERK1/2
Electronic supplementary material The online version of this article (doi:10.1007/s13277-014-2964-z) contains supplementary material, which is available to authorized users. Z. Ma : Y. Wang : Z. Li : H. Zhang : Z. Liu : J. Liu (*) Department of Orthopedic Surgery, The Second Hospital of Harbin Medical University, Harbin, Heilongjiang Province 150086, People’s Republic of China e-mail: [email protected] T. Piao Children’s Hospital of Harbin, Harbin, Heilongjiang Province 150010, People’s Republic of China
Introduction Osteosarcoma is the most common type of human primary malignant bone tumor, accounting for 60 % of all malignant childhood bone tumors [1–3]. Osteosarcoma usually occurs in the long bones, such as the femur, the tibia, or the humerus [4–6]. Approximately 50 % of these cases are localized near the knee region [7–9]. By combining surgery with other treatment (neoadjuvant chemotherapy and adjuvant chemotherapy), the 5-year survival of patients with no metastatic disease at diagnosis is about 60–70 % [10, 11]. Unfortunately, for patients who present with metastasis, the outcome is far worse at
